Journal of Neurology Neurosurgery and Psychiatry

Article	Citations
091 The East London Parkinson’s disease project – engaging a diverse population in research	138
175 A case series of anti-HMGCR immune mediated necrotizing myopathy: the West Midlands data	123
102 Levodopa and melanoma what do clinicians think?	107
117 Who is the culprit – the virus or the anti-virus?	102
Haemorrhagic myelitis as a manifestation of MOG antibody-associated disease	86
35 Processing speed (PS) improvement in alcohol related brain damage (ARBD)	85
Navigating the presymptomatic frontier in genetic ALS and FTD	82
086 Long-term efficacy of fremanezumab in migraine patients with inadequate response to prior preventive medication classes	80
West is best – a strongman with numb feet	76
12 A pilot investigation of interoceptive accuracy, awareness, and sensibility in functional neurological disorder	75
059 Cannabidiol in refractory adult epilepsies: broadening the Lennox-Gastaut phenotype?	70
Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts	69
Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning	67
101 Motor and non-motor features of prodromal PD	62
Neural (re)organisation of language and memory: implications for neuroplasticity and cognition	60
Sodium valproate is associated with cortical thinning of disease-specific areas in juvenile myoclonic epilepsy	56
Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis	55
High frequency ofHTRA1ANDABCC6mutations in Japanese patients with adult-onset cerebral small vessel disease	54
Improved naming in patients with Broca’s aphasia with tDCS	53
Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case/control cohort	53
Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis	52
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis	50
Early treatment of type II SMA slows rate of progression of scoliosis	50
DNA methylation profiling in central nervous system tumours	48
Characterising ALS disease progression according to El Escorial and Gold Coast criteria	48

052 SKYLINE study design efficacy and safety of gantenerumab in participants at-risk for Alzheimer’s disease	47
The Scottish Epilepsy Deaths Study Score (SEDS Score): a risk prediction model for epilepsy-related deaths	47
005 A case of xanthomatous hypophysitis presenting as recurrent pituitary adenoma	47
40 Temporal discounting and male depression	47
178 Motor neurone disease and sociodemographic factors: a review	46
Evaluation of MDS-PSP diagnostic criteria in a combined behavioural neurology and atypical parkinsonism service	44
066 The Utility of 18-FDG PET imaging in the preoperative workup for epilepsy surgery	44
055 Assessment of MACE cognitive screener using efficiency indexes	43
009 Asymmetric peri-optic cerebrospinal fluid space distension in cluster headache	42
132 Adverse prognostic factors predicting disease modifying therapies in MS: a real- world cohort	41
106 Critical ischaemia without infarction presenting as progressive hemichorea: a case study and literature review	41
Genetics of inherited peripheral neuropathies and the next frontier: looking backwards to progress forwards	40
Risk of stroke in multiple sclerosis and neuromyelitis optic spectrum disorder: a Nationwide cohort study in South Korea	40
Dissociative seizures in the emergency room: room for improvement	40
Multicentre validation of a patient-reported outcome measure for functional movement disorders	39
CIDP trials and tribulations	36
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunology	36
Relapse-associated worsening in apolipoprotein E ε4 carriers with relapsing multiple sclerosis	36
Patients with symmetric Parkinson’s disease do poorly with subthalamic stimulation	36
Comparative neural correlates of DBS and MRgFUS lesioning for tremor control in essential tremor	35
Real-world experience of gene therapy with onasemnogene-abeparvovec (Zolgensma®) for patients with SMA-type1 in UK	35
Intravenous methylprednisolone as add-on induction therapy for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial	35
Influence of cardiorespiratory fitness and MRI measures of neuroinflammation on hippocampal volume in multiple sclerosis	35
Association of obesity with mild traumatic brain injury symptoms, inflammatory profile, quality of life and functional outcomes: a TRACK-TBI Study	35
Induction cyclophosphamide with maintenance immunosuppression in high-risk myasthenia gravis: long-term follow-up and safety profile	35
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry	33
021 Experience from a SARS-CoV2 neurology clinic at the national hospital of neurology and neurosurgery	33
Spinal cord motor neuron phenotypes and polygenic risk scores in sporadic amyotrophic lateral sclerosis: deciphering the disease pathology and therapeutic potential of ropinirole hydrochloride	33
049 Hippocampal place cell dysfunction in an APP knock-in mouse model of Alzheimer’s disease	32
028 Croydon neurology diagnostic coding of outpatients – the first year of experience	32
099 Thrombotic and haemorrhagic complications associated with PLEX, reducing the risks	32
114 Pain and objectively measured cognitive performance in adults with multiple sclerosis: a systematic review	32
142 Discordance between neurologists and people with MS on the presence and burden of cognitive impairment	32
What, when and how should the information about neurodegenerative disease risk in iRBD be communicated?	32
156 Association of locus of control with clinical and psychosocial aspects of living with multiple sclerosis	31
010 Trigeminal neuralgia in diffuse scleroderma – a rare but recognised association	31
171 Urinary P75: a novel biomarker for motor neuron disease?	31
Quantification of muscle glycogen distribution in Pompe disease using 7 Tesla 13C NMR spectroscopy	30
Mechanistic biology linking traumatic brain injury to multiple sclerosis susceptibility	30
MRI lesions can often precede trigeminal neuralgia symptoms by years in multiple sclerosis	30
Gene-specific impacts on brain architecture in genetic frontotemporal dementia	29
Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis	29
Evoked mid-frontal activity predicts cognitive dysfunction in Parkinson’s disease	29
Searches for biomarkers using highly sensitive techniques might reveal more about pathogenesis of a disease than provide clinically useful molecular tests	28
185 JEWELFISH: Safety, pharmacodynamic and exploratory efficacy data in non-naïve patients with SMA receiving risdiplam	28
How effective is effective enough?	28
08 The economic cost of functional neurological disorders: a systematic review introduction	27
Validation of the hotspot for dorsolateral subthalamic nucleus targeting in deep brain stimulation surgery for Parkinson’s disease: a post hoc analysis of a randomised controlled trial	27
047 Clinicopathological characteristics impacting on survival in sporadic CJD: insights from an international autopsy-confirmed series	27
Serum level changes of the synaptic marker beta-synuclein in Alzheimer’s disease continuum and other dementias	27

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies	26
Insufficient sleep during adolescence and risk of multiple sclerosis: results from a Swedish case-control study	26
Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction	26
Cluster analysis showed long-term cognition can be predicted by looking at regional grey matter atrophy in the first two years of multiple sclerosis course	26
Beyond antithrombotics: recent advances in pharmacological risk factor management for secondary stroke prevention	26
058 Does prolonging duration of monitoring in epilepsy monitoring unit improve diagnostic yield?	25
054 Baseline characteristics of the Phase III GRADUATE studies: investigating subcu- taneous gantenerumab in early AD	25
Attenuated heart-brain integration predicts functional non-epileptic seizures	25
080 IIH Life A prospective longitudinal cohort study of idiopathic intracranial hypertension	25
A novel neurodegenerative disease with multi-system features	25
14 Saving Adam from the apple: using transcranial magnetic stimulation as a transdiagnostically relevant tool to decrease cue-reactivity	24
25 ‘In a mist?’ – What is ‘brain fog’?	24
11 The experience of hearing life altering medical news? Perspectives from health professionals	24
126 The provision of anti-CD20 therapy in inflammatory demyelinating disorders of the CNS during SARS-CoV-2	24
Relapse activity after assisted reproductive technology treatments in women with multiple sclerosis: a nationwide cohort study in Denmark	24
128 Visuoperceptual deficits as measures of cognitive dysfunction in multiple sclerosis: a pilot study	24
Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study	24
Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study	23
Comparison of relative change with effect size metrics in Alzheimer’s disease clinical trials	23
IVIg-exposure and thromboembolic event risk: findings from the UK Biobank	23
Ultrasensitive assay technology and fluid biomarkers for the evaluation of peripheral nerve disease	23
Association between heavy alcohol consumption and cryptogenic ischaemic stroke in young adults: a case–control study	23
Can CANVAS due toRFC1biallelic expansions present with pure ataxia?	23
Investigating colour vision and its structural correlates 15 years following a first demyelinating event	22
064 Epilepsy and sociodemographic factors a review	22
Peripheral hearing loss at age 70 predicts brain atrophy and associated cognitive change	22
Childbirth delivery mode and the risk of multiple sclerosis: a prospective population-based study	22
Dynamics of choroid plexus volume is associated with the presence and development of fatigue in multiple sclerosis	22
24 Intelligent sensing in ADHD trial (ISAT) – pilot study	22
Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis	22
Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations	21
Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort	21
Choroid plexus enlargement in paediatric multiple sclerosis: clinical relevance and effect of sex	21
056 Online assessment and monitoring of cognitive decline in neurological conditions	21
Gene–environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures	21
Visuospatial dysfunction predicts dementia-first phenoconversion in isolated REM sleep behaviour disorder	21
Epigenetic clocks in neurodegenerative diseases: a systematic review	21
Risk of secondary progressive multiple sclerosis after early worsening of disability	21
153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS)	21
032 Supine hypertension and cardiovascular autonomic failure in patients with alpha-synucleinopathies	21
Stratifying quality of life outcome in subthalamic stimulation for Parkinson’s disease	21
Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial	21
Prescription opioid use in multiple sclerosis	21
044 At what resolution does the brain perform computations?	21
Multiparametric quantitative MRI reveals progressive cortical damage over time in clinically stable relapsing-remitting MS	20
8 Integrating dimensions of interoception in neuropsychiatry	20
Time to treat the climate and nature crisis as one indivisible global health emergency	20
147 Siponimod preserves retinal thickness: findings from the EXPAND OCT substudy	20
Therapeutic interventions increasing seizure risk in multiple sclerosis: resolving discordant meta-analyses	20
04 Should neuropsychiatry flow both ways? Neurology inreach into psychiatric hospital	20
30 Dissociation and its biological and clinical correlates in functional neurological disorder: a systematic review and meta-analysis	19
Validation of MATCH score: a predictive tool for identification of patients with kelch-like protein-11 autoantibodies	19
37 The medicolegal challenges in neuropsychiatry: an evaluation of mental capacity and legal frameworks	19
Statin use and long-term risk of recurrent intracerebral haemorrhage: the MUCH-Italy	19
Structural and functional alterations in the gustatory network underlie taste disturbances after lesional tremor therapy with MRgFUS	19
Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA): a narrative review of interventional therapies	19
Beware next-generation sequencing gene panels as the first-line genetic test in Charcot-Marie-Tooth disease	18
Changes in the heartbeat-evoked potential are associated with functional seizures	18
Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study	18
Endovascular treatment for large-core ischaemic stroke: a meta-analysis of randomised controlled clinical trials	18
Elevated serum β-synuclein predicts cognitive decline and progression to dementia	18
Epilepsy surgery outcomes and their determinants: a systematic review and individual patient data meta-analysis	18
Characterising alexithymia in individuals with functional motor disorders: a cross-sectional analysis of the Italian Registry of Functional Motor Disorders	18
006 A novel approach in the management of functional neurological disorder in the hyper-acute setting	18
Telomere length, in vivo Alzheimer’s disease pathologies and cognitive decline in older adults	18
Neurocognitive and psychiatric outcomes associated with postacute COVID-19 infection without severe medical complication: a meta-analysis	18
We hold these truths to be self-evident	18
Incidence and prevalence of paediatric-onset multiple sclerosis in two Canadian provinces: a population-based study representing over half of Canada’s population	17
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, ph	17
100 Antiphospholipid-related chorea	17
Clinical biomarker-based biological ageing and future risk of neurological disorders in the UK Biobank	17
Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience	17
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study	17
Do lower limb motor-evoked potentials predict walking outcomes post-stroke?	17
023 Impact of pandemic on neurologists and neurology practice	17
Object naming after epilepsy surgery in the dominant left temporal lobe: risk factors, time course and long-term outcome	16
Head trauma results in manyfold increased risk of multiple sclerosis in genetically susceptible individuals	16
Safety of breast feeding during rituximab treatment in multiple sclerosis	16
21 How can we collaborate with experts-by-example to improve the ecological validity of computational psychiatry? A pilot study where the experts-by-experience are people with functional neurological	16
42 Inhibition of personal memory retrieval in dissociative amnesia: a study of two cases	16

067 One Health: Clinical characteristics of spontaneously-arising feline LGI1- autoantibody limbic encephalitis in a large international cohort	16
Strong association with remote EBV infection in children with MS as opposed to other acquired demyelinating disorders	16
152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis	16
Linking LRP12 CGG repeat expansion to inherited peripheral neuropathy	16
Parallel Session 2: Neurodegeneration| Wed 18 May, 1115 – 1230|4 Novel complex motor behaviours in LGI1-autoantibody encephalitis	16
073 Fenfluramine exhibits disease-modifying effects in a mouse model of Dravet syndrome	16
Temporal course of cognitive and behavioural changes in motor neuron diseases	16
Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: a national multicentre observational study	16
A roadmap to ALS prevention: strategies and priorities	16
Intrathecal Epstein–Barr virus reactivation in patients with autoimmune glial fibrillary acidic protein astrocytopathy	16
164 The role of MEG in assessment and diagnosis in mTBI	16
Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study	16
Poor sleep and multiple sclerosis: associations with symptoms of multiple sclerosis and quality of life	15
Distinguishing functional from primary tics: a study of expert video assessments	15
193 Unusual presentation of hereditary neuropathy with liability to pressure palsies (HNPP)	15
Silent burden: recognising and managing invisible symptoms in neuromyelitis optica	15
Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity	15
Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment	15
089 Re-admission rate for patients with headache in Southwest London – can this be addressed?	15
Parallel Session 1: Muscle, nerve and quality| Wed 18 May, 1115 – 1230|04 Project NeuroSafe: safety practice in neurology services	15
Endovascular therapy versus best medical management in distal medium middle cerebral artery acute ischaemic stroke: a multinational multicentre propensity score-matched study	15
Machine learning classification of functional neurological disorder using structural brain MRI features	15
Idiopathic intracranial hypertension: evaluation of births and fertility through the hospital episode statistic dataset 2002–2020	15
Paramagnetic rim and core sign lesions in paediatric multiple sclerosis patients	15
Multiple metal exposures associate with higher amyotrophic lateral sclerosis risk and mortality independent of genetic risk and correlate to self-reported exposures: a case-control study	15
The T1-weighted/T2-weighted ratio as a biomarker of anti-NMDA receptor encephalitis	15
061 The long-term effects of anterior temporal lobe resection on memory encoding: A longitudinal fMRI study	14
Preventing one disease is not enough for brain health	14
Blood biomarkers: ready for clinical practice?	14
Perception versus practice: the reality of functional neurological disorder (FND) diagnosis at a large neurological centre	14
Cavernomas: a randomised effectiveness (CARE) trial: treatment with versus without neurosurgery for symptomatic brain cavernoma	14
Pathophysiology, diagnosis and care of Alzheimer’s disease are coming together	14
Incidence of cerebral cavernous malformations among adults in Scotland: a prospective, population-based study	14
First-trimester use of antiseizure medications and the risk of miscarriage: a population-based cohort study	14
Code ICH: reorganising stroke care for intracerebral haemorrhage	14
205 Relationship between thrombin generation and micro-embolic signals in moderate-severe asymptomatic and symptomatic carotid stenosis patients	14
20 Reflexive downregulation of memory systems in dissociative amnesia: a case series	14
129 Multiple sclerosis relapse patterns in a population-based cohort	14
Phase 1 study of safety and preliminary efficacy of intranasal transplantation of human neural stem cells (ANGE-S003) in Parkinson’s disease	13
CSF ferritin in the clinicopathological progression of Alzheimer’s disease and associations with APOE and inflammation biomarkers	13
Kinematic analysis reliably assesses GPi-DBS effectiveness in dystonia	13
Nitrous oxide-induced myeloneuropathy: a case series	13
110 Outcome and mortality of hospital admission with COVID-19 for individuals with parkinsonian syndromes	13
Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting	13
Tract-specific white matter hyperintensities and neuropsychiatric syndromes: a multicentre memory clinic study	13
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum diso	13
Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies	13
Clinical and laboratory features of juvenile-onset anti-NF155 autoimmune nodopathy	13
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial	13
Motor cortex functional connectivity is associated with underlying neurochemistry in ALS	13
STN-DBS electrode placement accuracy and motor improvement in Parkinson’s disease: systematic review and individual patient meta-analysis	13
PACAP-38 is increased in the tear fluid of patients with migraine	13
Evolution of autonomic nervous system abnormalities in multiple sclerosis: a 6-year follow-up	13
Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy	13
063 The role of Monoclonal antibodies in contrasting cases of NORSE	12
Epilepsy mortality in Wales during COVID-19	12
Highlighting the past and future of inherited peripheral neuropathies	12
Long term outcomes of deep brain stimulation for treatment refractory chronic cluster headache and SUNHA	12
093 Screening of non-motor symptoms of Parkinson’s disease and dementia with Lewy bodies: clinical audit	12
094 Diffusion magnetic resonance imaging in dystonia: a review of methodological approaches and findings	12
01 Functional seizures and their misdiagnosis and mimics: a review of video-telemetry referrals and case outcomes in a tertiary epilepsy centre	12
Long-term outcomes of mesial temporal laser interstitial thermal therapy for drug-resistant epilepsy and subsequent surgery for seizure recurrence: a multi-centre cohort study	12
201 A case report of Collet Sicard syndrome	12
Language as a biomarker in dementia	12
Measurement properties of the Inclusion Body Myositis Functional Rating Scale	12
11 The epidemiology of infections as a risk factor for psychiatric illness	12
Recurrentde-novo gain-of-functionmutation inSPTLC2confirms dysregulated sphingolipid production to cause juvenile amyotrophic lateral sclerosis	11
CBD diagnostic criteria: exclusions as important as inclusions	11
Directional deep brain stimulation electrodes in Parkinson’s disease: meta-analysis and systematic review of the literature	11
Time to steroids impacts visual outcome of optic neuritis in MOGAD	11
Epilepsy-related premature mortality in adults with intellectual disability in England: a population-based analysis	11
Effects of motor cortical and peripheral axonal hyperexcitability on survival in amyotrophic lateral sclerosis	11
Proximity extension assay-based discovery of biomarkers for disease activity in chronic inflammatory demyelinating polyneuropathy	11
MYH7-related myopathies: clinical, myopathological and genotypic spectrum in a multicentre French cohort	11
Beyond the modified Rankin Scale: the unseen burden of stroke in young adults	11
Elevated plasma p-tau181 levels unrelated to Alzheimer’s disease pathology in amyotrophic lateral sclerosis	11
Six versus 2 weeks treatment with doxycycline in European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blinded, randomised and placebo-controlled trial	11
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders	11
Using prodromal non-motor symptoms to predict Parkinson’s disease onset and motor phenotype	11
Association of serum neurofilament light with microglial activation in multiple sclerosis	11
Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK	11
Prodromal phase of multiple sclerosis: evidence from sickness absence patterns before disease onset – a matched cohort study	11
Genetics impact risk of Alzheimer’s disease through mechanisms modulating structural brain morphology in late life	11
Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study	11
16 Comparing communication in face-to-face and telephone epilepsy consultations	10
Phenotypic spectrum of myelin protein zero-related neuropathies: a large cohort study from five mutation clusters across Italy	10
Identification of a pathogenic mutation inARPP21in patients with amyotrophic lateral sclerosis	10
Preoperative and postoperative memory in epilepsy patients with ‘gliosis only’ versus hippocampal sclerosis: a matched case–control study	10
Late-onset MSA differs from younger-onset MSA	10
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020	10
Disability accrual in primary and secondary progressive multiple sclerosis	10
Does stereotactic thrombolysis with alteplase for intracerebral haemorrhage alter intraventricular haematoma volume? A secondary analysis of the MISTIE-III trial	10
Autosomal recessive systemic microangiopathy associated withFANCLFanconi anaemia	10
Genotype–phenotype correlation and treatment effects in young patients withGNAO1-associated disorders	10
Incidence and prevalence of small fibre neuropathy in the Netherlands: a multiple system estimation study	10